Intellia Therapeutics Inc (NTLA) Sees Unusually-High Trading Volume
Intellia Therapeutics Inc (NASDAQ:NTLA) shares saw an uptick in trading volume on Thursday . 552,077 shares changed hands during trading, an increase of 114% from the previous session’s volume of 258,064 shares.The stock last traded at $21.98 and had previously closed at $21.08.
A number of research firms recently weighed in on NTLA. Jefferies Group reaffirmed a “buy” rating and set a $33.00 price target on shares of Intellia Therapeutics in a research note on Wednesday, August 17th. Leerink Swann assumed coverage on Intellia Therapeutics in a report on Tuesday, May 31st. They set a “market perform” rating and a $32.00 price objective for the company. Wedbush assumed coverage on Intellia Therapeutics in a report on Tuesday, May 31st. They set an “outperform” rating and a $38.00 price objective for the company. Zacks Investment Research lowered Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 3rd. Finally, Credit Suisse Group AG assumed coverage on Intellia Therapeutics in a report on Tuesday, May 31st. They set an “outperform” rating and a $39.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Intellia Therapeutics currently has a consensus rating of “Buy” and an average price target of $35.50.
The stock’s 50-day moving average is $19.41 and its 200-day moving average is $23.03. The firm’s market capitalization is $761.65 million.
Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.